Detalhe da pesquisa
1.
Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib.
Crit Rev Oncol Hematol
; 194: 104243, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38135019
2.
Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
Lung Cancer
; 174: 118-124, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36379124
3.
Is hyperprogressive disease a specific phenomenom of immunotherapy?
Explor Target Antitumor Ther
; 1(6): 427-433, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-36046388
4.
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study.
Lung Cancer
; 150: 123-131, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33130353